Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 1
2006 1
2007 1
2008 5
2009 4
2010 5
2011 18
2012 21
2013 19
2014 10
2015 8
2016 8
2017 6
2018 8
2019 10
2020 5
2021 5
2022 8
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 22139032

120 results

Results by year

Filters applied: . Clear all
Page 1
The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial.
Hansen TF, Christensen Rd, Andersen RF, Garm Spindler KL, Johnsson A, Jakobsen A. Hansen TF, et al. Int J Colorectal Dis. 2012 Jun;27(6):715-20. doi: 10.1007/s00384-011-1382-6. Epub 2011 Dec 6. Int J Colorectal Dis. 2012. PMID: 22139032 Clinical Trial.
Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
Loupakis F, Cremolini C, Yang D, Salvatore L, Zhang W, Wakatsuki T, Bohanes P, Schirripa M, Benhaim L, Lonardi S, Antoniotti C, Aprile G, Graziano F, Ruzzo A, Lucchesi S, Ronzoni M, De Vita F, Tonini G, Falcone A, Lenz HJ. Loupakis F, et al. PLoS One. 2013 Jul 4;8(7):e66774. doi: 10.1371/journal.pone.0066774. Print 2013. PLoS One. 2013. PMID: 23861747 Free PMC article.
Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
Gerger A, El-Khoueiry A, Zhang W, Yang D, Singh H, Bohanes P, Ning Y, Winder T, Labonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, Absenger G, Lenz HJ. Gerger A, et al. Clin Cancer Res. 2011 Sep 1;17(17):5783-92. doi: 10.1158/1078-0432.CCR-11-1115. Epub 2011 Jul 26. Clin Cancer Res. 2011. PMID: 21791631 Free PMC article.
Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab.
Koutras AK, Antonacopoulou AG, Eleftheraki AG, Dimitrakopoulos FI, Koumarianou A, Varthalitis I, Fostira F, Sgouros J, Briasoulis E, Bournakis E, Bafaloukos D, Bompolaki I, Galani E, Kalogeras KT, Pectasides D, Fountzilas G, Kalofonos HP. Koutras AK, et al. Pharmacogenomics J. 2012 Dec;12(6):468-75. doi: 10.1038/tpj.2011.37. Epub 2011 Aug 16. Pharmacogenomics J. 2012. PMID: 21844885 Clinical Trial.
Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
Ducreux M, Adenis A, Pignon JP, François E, Chauffert B, Ichanté JL, Boucher E, Ychou M, Pierga JY, Montoto-Grillot C, Conroy T. Ducreux M, et al. Eur J Cancer. 2013 Apr;49(6):1236-45. doi: 10.1016/j.ejca.2012.12.011. Epub 2013 Jan 24. Eur J Cancer. 2013. PMID: 23352604 Clinical Trial.
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer.
Loupakis F, Ruzzo A, Salvatore L, Cremolini C, Masi G, Frumento P, Schirripa M, Catalano V, Galluccio N, Canestrari E, Vincenzi B, Santini D, Bencardino K, Ricci V, Manzoni M, Danova M, Tonini G, Magnani M, Falcone A, Graziano F. Loupakis F, et al. BMC Cancer. 2011 Jun 14;11:247. doi: 10.1186/1471-2407-11-247. BMC Cancer. 2011. PMID: 21669012 Free PMC article.
aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
Fujita Y, Taguri M, Yamazaki K, Tsurutani J, Sakai K, Tsushima T, Nagase M, Tamagawa H, Ueda S, Tamura T, Tsuji Y, Murata K, Taira K, Denda T, Moriwaki T, Funai S, Nakajima TE, Muro K, Tsuji A, Yoshida M, Suyama K, Kurimoto T, Sugimoto N, Baba E, Seki N, Sato M, Shimura T, Boku N, Hyodo I, Yamanaka T, Nishio K. Fujita Y, et al. Oncologist. 2019 Mar;24(3):327-337. doi: 10.1634/theoncologist.2018-0119. Epub 2018 Nov 13. Oncologist. 2019. PMID: 30425180 Free PMC article. Clinical Trial.
120 results